BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 30197475)

  • 1. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
    Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
    World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ; Sydora BC; Fedorak RN
    J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.
    Rokkas T; Portincasa P; Koutroubakis IE
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):299-306. PubMed ID: 30240474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
    J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
    Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
    World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
    Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
    Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
    Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
    Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
    Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
    Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.
    Lin WC; Wong JM; Tung CC; Lin CP; Chou JW; Wang HY; Shieh MJ; Chang CH; Liu HH; Wei SC;
    World J Gastroenterol; 2015 Dec; 21(48):13566-73. PubMed ID: 26730169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.